FLDM - Fluidigm Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.01
-0.13 (-1.07%)
As of 12:39PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close12.14
Open12.20
Bid11.94 x 800
Ask11.97 x 800
Day's Range11.93 - 12.52
52 Week Range4.65 - 14.90
Volume275,836
Avg. Volume735,158
Market Cap828.929M
Beta (3Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire11 days ago

    Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of May 7, 2019, under Fluidigm’s 2017 Inducement Award Plan (Plan), as a material inducement to thirteen individuals entering into employment with Fluidigm. In connection with the individuals entering into employment with Fluidigm as new employees, none of whom were previously employees or directors of Fluidigm, the individuals received awards totaling an aggregate of 66,600 restricted stock units (RSU Awards).

  • GlobeNewswire12 days ago

    Fluidigm to Participate in Upcoming Health Care Investor Conferences

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor conferences. Chris Linthwaite, President and Chief Executive Officer, will participate in a fireside chat regarding Fluidigm’s business strategy and financial performance on Tuesday, May 21, 2019 at 11:30 ET at the UBS Global Healthcare Conference in New York. Vikram Jog, Chief Financial Officer, is scheduled to present on Tuesday, June 4, 2019, at 1:30 pm ET regarding Fluidigm’s business strategy and financial performance at the Jefferies 2019 Healthcare Conference in New York.

  • GlobeNewswire19 days ago

    Fluidigm Announces First Quarter 2019 Financial Results

    First quarter revenue increased 19 percent to $30.1 million Mass cytometry revenue growth of 110 percent in first quarter Strong mass cytometry and Imaging Mass Cytometry.

  • GlobeNewswire19 days ago

    Leading Cancer Center in Japan Selects Hyperion Imaging System to Expand Immuno-Oncology Research Studies in Colorectal Cancer

    Fluidigm Corporation (FLDM) announced today that the Group for Innovative Cancer Treatment Division of the National Cancer Center in Japan has expanded its clinical research in colorectal cancer using the Hyperion™ Imaging System to study regulatory T (Treg) cell proliferation in tumor tissue with the goal of discovering a novel target for immunotherapy.

  • GlobeNewswire21 days ago

    Fluidigm Announces 8th Annual Mass Cytometry Summit

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will hold the 8th Annual Fluidigm Mass Cytometry Summit on June 20 and 21, 2019, at the Pinnacle Hotel Harbourfront in Vancouver, Canada. The Summit brings together translational researchers from around the world to discuss new mass cytometry research applications and best practices for identifying biomarker signatures in health and disease and accelerating therapeutic development. “We are excited to hold this year’s Summit right before CYTO® 2019,” said Chris Linthwaite, President and CEO of Fluidigm.

  • GlobeNewswire2 months ago

    Fluidigm Announces Conference Call and Webcast of First Quarter 2019 Financial Results

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2019 financial results on Thursday, May 2, 2019, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:00 p.m. PT / 5:00 p.m. ET on May 2, 2019, to discuss first quarter financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

  • GlobeNewswire2 months ago

    Fluidigm Showcases New Product Innovations and Research Presentations at the 2019 American Association for Cancer Research (AACR) Meeting

    SOUTH SAN FRANCISCO, Calif., March 28, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through.

  • GlobeNewswire2 months ago

    Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry

    Fluidigm Corporation (FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the introduction of the Maxpar® Direct™ Immune Profiling System. Setting the new standard in immune profiling, the system empowers researchers to easily quantify 37 different immune cell populations from human peripheral blood mononuclear cells (PBMC) and whole blood using a simple single-tube workflow with automated five-minute results reporting. In the past two years alone, clinical trials utilizing immune cell profiling have grown by more than 30 percent, with more than 35,000 patients enrolled.

  • GlobeNewswire3 months ago

    Colin McCracken Joins Fluidigm as Chief Commercial Officer

    Fluidigm Corporation (FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and existing markets and expanding the company’s global reach. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, McCracken will advance Fluidigm’s commercialization infrastructure and organization toward further market adoption of the company’s products, particularly in the growing scientific community studying the human immune system.

  • GlobeNewswire3 months ago

    Fluidigm to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.

  • GlobeNewswire3 months ago

    Detailed Research: Economic Perspectives on Exxon Mobil, Loxo Oncology, Fluidigm, LHC Group, Ebix, and Omega Flex — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire3 months ago

    Fluidigm Announces Fourth Quarter and Full Year 2018 Financial Results

    Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to.

  • GlobeNewswire3 months ago

    Fluidigm Announces Co-Marketing Agreement with Indica Labs to Offer Platform for Imaging Mass Cytometry Data Analysis to Aid Novel Digital Pathology Investigations

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 -- Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and.

  • GlobeNewswire3 months ago

    Fluidigm Announces Participation in Life Science/Pharma and Academic Consortium to Study T Cell-Driven Immune-Mediated Inflammatory Diseases

    Fluidigm Corporation (FLDM) today announced it is one of 11 partners in the TIMID Consortium, a unique effort of six academic institutions and five life science and pharma companies that utilizes both mass cytometry and Imaging Mass Cytometry™ along with other technologies to explore the common cellular basis of T cell-driven immune-mediated inflammatory diseases (IMIDs). The research will potentially empower more precise treatments using existing drugs and identify new targets for future drug development.

  • GlobeNewswire4 months ago

    Fluidigm Introduces REAP-Seq for Multi-Omic Single-Cell Analysis on the C1

    SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of.

  • GlobeNewswire4 months ago

    Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results

    SOUTH SAN FRANCISCO, Calif., Jan. 14, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report.

  • GlobeNewswire4 months ago

    Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring

    SOUTH SAN FRANCISCO, Calif. and MONTREAL, Jan. 08, 2019 -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing.

  • GlobeNewswire5 months ago

    Fluidigm Announces Closing of Public Offering of 9,372,500 Shares of Common Stock Including Full Exercise of Option to Purchase Additional Shares

    Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced the closing of its previously announced underwritten public offering of 9,372,500 shares of its common stock. The shares include 1,222,500 shares of common stock sold pursuant to an over-allotment option granted by Fluidigm to the underwriters, which option was exercised in full. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies, and to fund possible investments in or acquisitions of complementary businesses, products, or technologies.

  • GlobeNewswire5 months ago

    Fluidigm Announces Pricing of Public Offering of 8,150,000 Shares of Common Stock

    Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced the pricing of an underwritten public offering of 8,150,000 shares of its common stock at a price to the public of $6.75 per share for aggregate gross proceeds of approximately $55 million. Fluidigm has granted to the underwriters of the offering a 30-day option to purchase up to an additional 1,222,500 shares of common stock at the public offering price. Fluidigm intends to use the net proceeds of the offering for general corporate purposes, including working capital, capital expenditures and continued research and development with respect to products and technologies.  The offering is expected to close on or about December 14, 2018, subject to customary closing conditions.

  • GlobeNewswire5 months ago

    Fluidigm Announces Commencement of Public Offering of Common Stock

    Fluidigm Corporation (FLDM), a leader in mass cytometry and microfluidics technologies, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering pursuant to Fluidigm’s existing shelf registration statement. Piper Jaffray and UBS Investment Bank are acting as joint book-running managers for the offering. A shelf registration statement on Form S-3 relating to the common stock offered in the public offering described above was filed with the Securities and Exchange Commission (SEC) on March 8, 2017, amended on April 28, 2017 and declared effective by the SEC on May 2, 2017.  The offering will be made only by means of a written prospectus and prospectus supplement.

  • GlobeNewswire6 months ago

    Fluidigm to Participate in the 30th Annual Piper Jaffray Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s.

  • GlobeNewswire6 months ago

    Fluidigm Showcases Immuno-Oncology Innovations for Translational and Clinical Research at SITC 2018

    A comprehensive suite of innovative immuno-oncology applications to improve the future of cancer care SOUTH SAN FRANCISCO, Calif., Nov. 08, 2018 -- Fluidigm Corporation.